Chitosan nanoparticles loaded with aspirin and 5‐fluororacil enable synergistic antitumour activity through the modulation of NF‐κB/COX‐2 signalling pathway

Wang, Peng; Shen, Yulong; Zhao, Liang

doi:10.1049/iet-nbt.2020.0002

Cited by 14 publications

(7 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, the beneficial effects of ASA on inflammation can also be explained by the decreased expression of COX-1, COX-2, TNFα, and IL-6 and the increased expression of anti-inflammatory IL-10. The inhibitory effect of ASA on COX-2 expression has also been shown in other recent studies, but the decrease in COX-2 expression could be promoted by the reduced levels of TNF-α as well [ 20 , 21 , 22 , 23 , 24 ]. In line with the results of our study, it has been shown that, in mice fed with a methionine- and choline-deficient diet, hepatic expression of COX-2 messenger RNA and protein was significantly higher than controls, paralleling the increase in the levels of TNF-α and IL-6 and the development of steatohepatitis; pharmacological inhibition of COX-2 ameliorated the severity of experimental steatohepatitis [ 25 ].…”

Section: Discussionsupporting

confidence: 62%

Low-Dose Acetylsalicylic Acid and Mitochondria-Targeted Antioxidant Mitoquinone Attenuate Non-Alcoholic Steatohepatitis in Mice

et al. 2023

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease. NAFLD can evolve from simple fatty liver to non-alcoholic steatohepatitis (NASH), and ultimately, to cirrhosis. Inflammation and oxidative stress, promoted by mitochondrial dysfunction, play a crucial role in the onset and development of NASH. To date, no therapy has been approved for NAFLD and NASH. The aim of this study is to evaluate if the anti-inflammatory activity of acetylsalicylic acid (ASA) and the mitochondria-targeted antioxidant effect of mitoquinone could hinder the progression of non-alcoholic steatohepatitis. In mice, fatty liver was induced through the administration of a deficient in methionine and choline and rich in fat diet. Two experimental groups were treated orally with ASA or mitoquinone. Histopathologic evaluation of steatosis and inflammation was performed; the hepatic expression of genes associated with inflammation, oxidative stress, and fibrosis was evaluated; the protein expression of IL-10, cyclooxygenase 2, superoxide dismutase 1, and glutathione peroxidase 1 in the liver was analyzed; a quantitative analysis of 15-epi-lipoxin A4 in liver homogenates was performed. Mitoquinone and ASA significantly reduced liver steatosis and inflammation by decreasing the expression of TNFα, IL-6, Serpinb3, and cyclooxygenase 1 and 2 and restoring the anti-inflammatory IL-10. Treatment with mitoquinone and ASA increased the gene and protein expression of antioxidants, i.e., catalase, superoxide dismutase 1, and glutathione peroxidase 1, and decreased the expression of profibrogenic genes. ASA normalized the levels of 15-epi-Lipoxin A4. In mice fed with a deficient in methionine and choline and rich in fat diet, mitoquinone and ASA reduce steatosis and necroinflammation and may represent two effective novel strategies for the treatment of non-alcoholic steatohepatitis.

show abstract

Section: Discussionsupporting

confidence: 62%

Low-Dose Acetylsalicylic Acid and Mitochondria-Targeted Antioxidant Mitoquinone Attenuate Non-Alcoholic Steatohepatitis in Mice

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Transcription of COX-2 is thought to be promoted by NF-κB. Aspirin modifies both NF-κB signaling and COX-2 expression ( 116 ), and has been shown to have therapeutic effects in several tumors with high COX-2 levels ( 117 , 118 ). Although some studies have shown that aspirin may halt VS growth ( 119 , 120 ), the latest meta-analysis disproved this viewpoint ( 121 ).…”

Section: Resultsmentioning

confidence: 99%

“…have therapeutic effects in several tumors with high COX-2 levels (117,118). Although some studies have shown that aspirin may halt VS growth (119,120), the latest meta-analysis disproved this viewpoint (121).…”

Section: Cyclooxygenase-2 (Cox-2)mentioning

confidence: 99%

Potential Molecular Biomarkers of Vestibular Schwannoma Growth: Progress and Prospects

et al. 2021

View full text Add to dashboard Cite

Vestibular schwannomas (VSs, also known as acoustic neuromas) are relatively rare benign brain tumors stem from the Schwann cells of the eighth cranial nerve. Tumor growth is the paramount factor for neurosurgeons to decide whether to choose aggressive treatment approach or careful follow-up with regular magnetic resonance imaging (MRI), as surgery and radiation can introduce significant trauma and affect neurological function, while tumor enlargement during long-term follow-up will compress the adjacent nerves and tissues, causing progressive hearing loss, tinnitus and vertigo. Recently, with the deepening research of VS biology, some proteins that regulate merlin conformation changes, inflammatory cytokines, miRNAs, tissue proteins and cerebrospinal fluid (CSF) components have been proposed to be closely related to tumor volume increase. In this review, we discuss advances in the study of biomarkers that associated with VS growth, providing a reference for exploring the growth course of VS and determining the optimal treatment strategy for each patient.

show abstract

“…Additionally, some literature reports include combined targeting of different reactive agents to obtain synergistic antitumor activity. Based on this assumption, nonsteroidal anti-inflammatory aspirin was co-loaded with 5-FU in chitosan NPs [ 63 ]. Aspirin contributed to reduced cell viability and thus strengthened the antitumor effect of 5-FU.…”

Section: Cs Np Platforms For a Specific Drug Deliverymentioning

confidence: 99%

Chitosan-Based Nanoparticles with Optimized Parameters for Targeted Delivery of a Specific Anticancer Drug—A Comprehensive Review

Kurczewska

2023

Pharmaceutics

View full text Add to dashboard Cite

Chitosan is a positively charged polysaccharide obtained through chitin deacetylation. It belongs to a group of biodegradable, bioavailable, and non-toxic materials of natural origin; thus, it is a promising matrix for creating delivery systems of different active agents. Recently, much attention has been paid to nanodelivery systems as carriers to enable better bioavailability, and thus higher efficiency of the loaded drug. The present review is focused on the progress in chitosan-based nanoparticles for the targeted delivery of antitumor drugs. The paper discusses literature reports from the last three years in which chitosan nanoparticles were applied as carriers for active substances used in antitumor therapy and potential new drugs with anticancer properties. Special attention was paid to the different treatments applied to increase the therapeutic effectiveness and minimize the side effects of a specific active substance.

show abstract

Chitosan nanoparticles loaded with aspirin and 5‐fluororacil enable synergistic antitumour activity through the modulation of NF‐κB/COX‐2 signalling pathway

Cited by 14 publications

References 35 publications

Low-Dose Acetylsalicylic Acid and Mitochondria-Targeted Antioxidant Mitoquinone Attenuate Non-Alcoholic Steatohepatitis in Mice

Low-Dose Acetylsalicylic Acid and Mitochondria-Targeted Antioxidant Mitoquinone Attenuate Non-Alcoholic Steatohepatitis in Mice

Potential Molecular Biomarkers of Vestibular Schwannoma Growth: Progress and Prospects

Chitosan-Based Nanoparticles with Optimized Parameters for Targeted Delivery of a Specific Anticancer Drug—A Comprehensive Review

Contact Info

Product

Resources

About